Aethlon Medical is a clinical-stage medical device company developing the Hemopurifier, an extracorporeal blood filtration device. The Hemopurifier uses a proprietary lectin affinity resin to capture and remove extracellular vesicles (EVs) and enveloped viruses from the bloodstream. Aethlon focuses its clinical development on oncology, specifically for patients with solid tumors who are unresponsive to anti-PD-1 immunotherapy. Aethlon aims to restore a patient's immune response to tumors by removing immunosuppressive EVs from circulation. The company is currently conducting safety and dose-finding trials in Australia to test the device with varying frequencies of treatment. Aethlon is pre-commercial with no current revenue and funds its operations through equity issuance. Aethlon's business strategy relies on generating clinical data to secure a strategic partnership with a larger pharmaceutical or medical device firm to fund late-stage trials and commercialization. While oncology is its primary focus, Aethlon maintains an open pathway for viral indications and conducts preclinical research for applications in Long COVID and autoimmune diseases. Aethlon utilizes contract manufacturing and external research organizations for its operations. To improve future adoption, Aethlon is exploring the use of simplified blood pump systems that would allow treatments to occur in oncology infusion centers rather than traditional dialysis units.